Journal ArticleDOI
Vorinostat-induced bone loss might be related to drug toxicity.
Reads0
Chats0
Citations
More filters
Journal ArticleDOI
Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors - What Some May Have Forgotten or Would Rather Forget?
Sida Shen,Alan P. Kozikowski +1 more
TL;DR: It is concluded that the hydroxamate group, while providing high‐potency HDACIs, is not necessarily the best zinc‐binding group for HDACI drug discovery.
Journal ArticleDOI
TGF-β 1 impairs mechanosensation of human osteoblasts via HDAC6-mediated shortening and distortion of primary cilia
Sabrina Ehnert,Vrinda Sreekumar,Romina H. Aspera-Werz,Sahar Olsadat Sajadian,Elke Wintermeyer,Gunther H. Sandmann,Christian Bahrs,Jan G. Hengstler,Patricio Godoy,Andreas K. Nussler +9 more
TL;DR: TGF-β1 impairs human osteoblast maturation partially via HDAC6-mediated distortion and/or shortening of primary cilia, which opens up new treatment options for trauma patients with chronically elevated TGF- β1-levels.
Journal ArticleDOI
HDAC6 as a potential therapeutic target for peripheral nerve disorders.
TL;DR: Histone deacetylase 6 (HDAC6) should be further investigated as a preventative measure and therapeutic strategy for inherited and acquired peripheral neuropathies and non-hydroxamic acid-based HDAC6i should be the focus of the future research.
Journal ArticleDOI
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
TL;DR: In this article, the structure-activity relationships (SARs) of mercaptoacetamide-based HDAC6is are discussed at the molecular level using inhibitor-HDAC co-crystal structures, and a perspective regarding their drug metabolism, pharmacokinetics, and pharmacological properties.
References
More filters
Journal ArticleDOI
A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow
Masoud Soleimani,Samad Nadri +1 more
TL;DR: A protocol for straightforward isolation and culture of mesenchymal stem cells (MSCs) from mouse bone marrow (BM) is explained to supply researchers with a method that can be applied in cell biology and tissue engineering with minimal requirements.
Journal ArticleDOI
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros,Angelika M. Burger,Sunita Philip,Ruben Niesvizky,Sarah Kolla,Olga Goloubeva,Carolynn Harris,James A. Zwiebel,John Wright,Igor Espinoza-Delgado,Maria R. Baer,Julianne L. Holleran,Merrill J. Egorin,Steven Grant +13 more
TL;DR: The maximum tolerated dose of vorinostat in the study was 400 mg daily for 8 days every 21 days, with bortezomib administered at a dose of 1.3 mg/m2 on days 1, 4, 8, and 11, and the promising antimyeloma activity of the regimen in refractory patients merits further evaluation.
Journal ArticleDOI
Histone Deacetylase Inhibitors Promote Osteoblast Maturation
TL;DR: It is shown that several HDIs promote osteoblast maturation in vitro and in calvarial organ cultures.
Journal ArticleDOI
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
Paul G. Richardson,Constantine S. Mitsiades,Kathleen Colson,Eileen Reilly,Laura McBride,Judy Chiao,L. Sun,Justin L. Ricker,Syed Rizvi,Carol Oerth,Barbara Atkins,Ivy Fearen,Kenneth C. Anderson,David Siegel +13 more
TL;DR: Of 10 evaluable patients, 1 had a minimal response and 9 had stable disease, demonstrating modest single-agent activity in relapsed/refractory multiple myeloma, and maximum tolerated doses (MTDs) were determined.
Journal ArticleDOI
Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation.
TL;DR: Examination of expression levels of HDACs and the degree of histone acetylation at the promoter regions of osteogenic genes proposed that down-regulation ofHDAC1 is an important process for osteogenesis.